Glenmark Pharma Received Approval For Tacrolimus Capsules Thus Expand Its Presence In The Global Tacrolimus Market

 

Tacrolimus Market


Growing organ transplant procedures around the globe are driving the growth of the Tacrolimus market. It is mostly used as an immunosuppressant after organ transplant procedures application.  This is expected to increase organ transplant procedures. Moreover, improvement in the transplantation procedure such as feasibility and a better understanding of immunology is again expected to foster the growth of the market. For instance, in February 2021, India-based generics makers Biocon and Lupin have both launched generic tacrolimus capsules in the US. It had launched tacrolimus capsules at doses of 0.5 mg, 1 mg, and 5 mg.

1.      In June 2020, Sandoz announced the launch of once-daily generic tacrolimus capsules known as Dailiport® in Germany, the UK, Netherlands, Finland, Sweden, Estonia, Latvia, Slovakia, and as Conferoport® in Italy and Spain

2.      In March 2019, Astellas announced the launch of PROGRAF® Granules (tacrolimus for oral suspension) in the United States. PROGRAF is used in combination with other immunosuppressants to help prevent organ rejection in people who have had a liver, heart, or kidney transplant.

3.      In November 2020, Glenmark Pharma announced that it has received final approval from the US health regulator for Tacrolimus capsules, used as immuno-suppressant.

4.      In October 2020, Aequus Pharmaceuticals Inc. announced that it has agreed to an extension of terms for its promotional service agreement with Sandoz Canada Inc. (“Sandoz”) on tacrolimus immediate-release (“Tacrolimus IR”) to December 31st, 2021

5.      In June 2020, TFF Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Tacrolimus Inhalation Powder for prophylaxis of lung allograft rejection

North America is expected to lead the global Tacrolimus market in the near future and this is attributed to the high number of organ transplant procedures in the region. In 2019, a total of 3,014 organ transplant procedures were performed in Canada, according to the latest data from the Canadian Organ Replacement Register (CORR) — a pan-Canadian information system for organ failure in Canada. The need for renal replacement therapy in Canada is growing: the rate of new patients starting therapy increased 1.6% a year on average between 2010 and 2019.

Tacrolimus is a type of immunosuppressant which is majorly used after organ transplant procedures in order to prevent organ rejection. It inhibits the initiation of serine-threonine phosphatase, calcineurin, in T lymphocytes. This suppresses the activation of T lymphocytes and subsequent generation of cytotoxic lymphocytes hence suppresses the process of organ rejection.

Comments

Popular posts from this blog

Astrum Has Expanded Its Presence In India Infrared Thermometer Market

The Global Meningococcal Vaccines Market Continues To Grow Owing To the Demand from Healthcare Care Sectors across the World to Prevent the Spread of the Diseases Especially In Children

Increasing Geriatric Population Is Driving the Growth of the Sexual Health Market